Semaglutide vs Tirzepatide vs Retatrutide for Women
Women have unique considerations when choosing a GLP-1 medication, from hormonal effects and fertility implications to menopause-related weight distribution and PCOS management. Here is how semaglutide, tirzepatide, and retatrutide compare specifically for women's health goals and concerns.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All three medications are contraindicated during pregnancy. Discuss your specific health profile with your healthcare provider to determine the best medication for you.
Head-to-Head Comparison
| Factor | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Average Weight Loss | 12-15% | 15-22% | 20-24% |
| Mechanism | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Cost (Trimi) | $125/month | $125/month | Contact for pricing |
| Fertility Impact | Improved via weight loss | Improved via weight loss | Improved via weight loss |
| PCOS Benefit | Good | Better (dual insulin mechanism) | Best (triple mechanism) |
| Nausea Rate | 40-45% | 35-40% | 40-45% |
| Hair Thinning Risk | Moderate | Moderate-High (faster loss) | Higher (most rapid loss) |
| Clinical Data | Most extensive | Extensive | Phase 2 (emerging) |
Women-Specific Considerations
Hormonal Effects
All three medications can affect menstrual cycles through weight loss-driven hormonal changes. Estrogen is stored in fat tissue, so significant fat loss can alter estrogen levels. This can cause:
- Temporary menstrual irregularity during active weight loss
- Restored menstrual regularity in women with obesity-related amenorrhea
- Improved ovulation in women with anovulatory cycles
Tirzepatide and retatrutide, with their greater weight loss, may cause more pronounced hormonal shifts. Women in perimenopause should discuss hormone monitoring with their provider.
Fertility and Contraception
All three medications improve fertility through weight loss. This is particularly important because:
- Improved ovulation can occur within weeks, before significant weight loss is visible
- All GLP-1 medications are contraindicated during pregnancy
- Oral contraceptives may be less effective due to slowed gastric absorption
- Non-oral contraceptive methods (IUD, implant, injection) are recommended during GLP-1 therapy
PCOS
For women with PCOS, tirzepatide may have an edge over semaglutide because the GIP receptor activation provides additional insulin-sensitizing effects beyond GLP-1 alone. Insulin resistance is the central metabolic driver of PCOS. Retatrutide adds glucagon receptor activation, which may further improve metabolic outcomes.
Menopause
Menopausal weight gain tends to centralize around the abdomen (visceral fat). GLP-1 medications preferentially reduce visceral fat. Retatrutide's glucagon component specifically targets hepatic fat, which is particularly beneficial for postmenopausal women who are at higher risk for fatty liver disease.
Loose Skin and Appearance
Faster weight loss (tirzepatide and retatrutide) increases the risk of loose skin. Women tend to carry more subcutaneous fat than men, and skin elasticity decreases with age. If loose skin is a primary concern, slower weight loss with semaglutide may be preferable, paired with collagen supplementation and strength training.
Bone Health
Rapid weight loss can decrease bone density, a concern for postmenopausal women who are already at risk for osteoporosis. All three medications carry this risk proportional to the amount of weight lost. Adequate calcium, vitamin D, and weight-bearing exercise are essential. DEXA scans should be considered for postmenopausal women on GLP-1 therapy.
Recommendations by Life Stage
- Pre-menopausal, no fertility plans: Tirzepatide offers the best balance of efficacy and safety data
- Pre-menopausal, future fertility plans: Semaglutide (most safety data, easier to time discontinuation) or tirzepatide
- PCOS: Tirzepatide (superior insulin sensitization) or retatrutide if available
- Perimenopausal: Any of the three, with hormone level monitoring
- Postmenopausal: Tirzepatide or retatrutide for visceral fat reduction, with bone density monitoring
Find Your Best Fit with Trimi
Trimi's medical team helps women choose the right GLP-1 medication for their specific health profile. Compounded semaglutide is $99/month and compounded tirzepatide is $125/month. Visit our treatment page to get started.
Frequently Asked Questions
Which GLP-1 causes the least hair loss in women?
Hair thinning (telogen effluvium) is related to the rate of weight loss rather than the specific medication. Semaglutide, with its typically slower weight loss, may cause less hair thinning than tirzepatide or retatrutide. Adequate protein (100+ grams daily), biotin, and iron supplementation help minimize this effect regardless of medication choice.
Can I take GLP-1 while breastfeeding?
GLP-1 medications are not recommended during breastfeeding due to insufficient safety data. Wait until you have fully weaned before restarting or starting GLP-1 therapy.
Will GLP-1 affect my birth control?
GLP-1 medications slow gastric emptying, which can reduce absorption of oral contraceptives. Switch to a non-oral method (IUD, implant, injection, patch, or ring) for reliable contraception during GLP-1 therapy.
More on 3-Way Comparisons
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).